Iron-catalysed C–H ortho-arylation of edaravone, a promising monoamine oxidase-B inhibitor

Soneela Asghar; Mattia Manzotti; Alexander Atkins; Sanita Tailor; Hazel a. Sparkes; Muhammad Saeed; Robin b. Bedford

doi:10.1016/j.tet.2024.133983

Iron-catalysed C–H ortho-arylation of edaravone, a promising monoamine oxidase-B inhibitor

Soneela Asghar, Mattia Manzotti, Alexander Atkins, Sanita Tailor, Hazel a. Sparkes, Muhammad Saeed, Robin b. Bedford^*

^*Corresponding author for this work

School of Chemistry

Research output: Contribution to journal › Article (Academic Journal) › peer-review

Abstract

Edaravone is a neuroactive drug that is currently used in the treatment of stroke patients and shows promise against a range of neurodegenerative processes including amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease. We show that iron-catalysed C–H functionalisation of edaravone and its derivatives can be exploited to generate a small library of 21 arylated edaravones, while the results of a preliminary computational binding study of these derivatives predicts that they should all bind more strongly in the active site of monoamine oxidase-B than edaravone.

Original language	English
Article number	133983
Pages (from-to)	1-7
Number of pages	7
Journal	Tetrahedron
Volume	158
DOIs	https://doi.org/10.1016/j.tet.2024.133983
Publication status	Published - 30 May 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors

Access to Document

10.1016/j.tet.2024.133983Licence: CC BY

Handle.net

Persistent link

Cite this

@article{0096b0b31c0f401eb5ecdcac52068b8a,

title = "Iron-catalysed C–H ortho-arylation of edaravone, a promising monoamine oxidase-B inhibitor",

abstract = "Edaravone is a neuroactive drug that is currently used in the treatment of stroke patients and shows promise against a range of neurodegenerative processes including amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease. We show that iron-catalysed C–H functionalisation of edaravone and its derivatives can be exploited to generate a small library of 21 arylated edaravones, while the results of a preliminary computational binding study of these derivatives predicts that they should all bind more strongly in the active site of monoamine oxidase-B than edaravone.",

author = "Soneela Asghar and Mattia Manzotti and Alexander Atkins and Sanita Tailor and Sparkes, {Hazel a.} and Muhammad Saeed and Bedford, {Robin b.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2024",

month = may,

day = "30",

doi = "10.1016/j.tet.2024.133983",

language = "English",

volume = "158",

pages = "1--7",

journal = "Tetrahedron",

issn = "0040-4020",

publisher = "Elsevier",

}

TY - JOUR

T1 - Iron-catalysed C–H ortho-arylation of edaravone, a promising monoamine oxidase-B inhibitor

AU - Asghar, Soneela

AU - Manzotti, Mattia

AU - Atkins, Alexander

AU - Tailor, Sanita

AU - Sparkes, Hazel a.

AU - Saeed, Muhammad

AU - Bedford, Robin b.

PY - 2024/5/30

Y1 - 2024/5/30

N2 - Edaravone is a neuroactive drug that is currently used in the treatment of stroke patients and shows promise against a range of neurodegenerative processes including amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease. We show that iron-catalysed C–H functionalisation of edaravone and its derivatives can be exploited to generate a small library of 21 arylated edaravones, while the results of a preliminary computational binding study of these derivatives predicts that they should all bind more strongly in the active site of monoamine oxidase-B than edaravone.

AB - Edaravone is a neuroactive drug that is currently used in the treatment of stroke patients and shows promise against a range of neurodegenerative processes including amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease. We show that iron-catalysed C–H functionalisation of edaravone and its derivatives can be exploited to generate a small library of 21 arylated edaravones, while the results of a preliminary computational binding study of these derivatives predicts that they should all bind more strongly in the active site of monoamine oxidase-B than edaravone.

U2 - 10.1016/j.tet.2024.133983

DO - 10.1016/j.tet.2024.133983

M3 - Article (Academic Journal)

SN - 0040-4020

VL - 158

SP - 1

EP - 7

JO - Tetrahedron

JF - Tetrahedron

M1 - 133983

ER -

Iron-catalysed C–H ortho-arylation of edaravone, a promising monoamine oxidase-B inhibitor

Abstract

Bibliographical note

Access to Document

Handle.net

Fingerprint

Cite this